CSL Limited (CMXHF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Melbourne, VIC, Australia. The current CEO is Gordon Naylor DipCompSc.
CMXHF has IPO date of 2005-11-18, 32,698 full-time employees, listed on the Other OTC, a market capitalization of $46.79B.
CSL Limited is a global biopharmaceutical company founded in 1916 and headquartered in Parkville, Australia. The company researches, develops, manufactures, and distributes biopharmaceutical products across Australia, the United States, Europe, China, and other international markets. Operating through two main divisions—CSL Behring and Seqirus—the company specializes in plasma-derived therapies for immunodeficiency, bleeding disorders, and neurological conditions, as well as non-plasma biotherapeutics and influenza-related products. CSL Behring also generates revenue through licensing and royalties on intellectual property commercialization.
